N E Davidson
Overview
Explore the profile of N E Davidson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
4158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, DellOrto P, et al.
Ann Oncol
. 2023 Jan;
34(4):397-409.
PMID: 36709040
Background: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that...
2.
Rakovitch E, Gray R, Baehner F, Sutradhar R, Crager M, Gu S, et al.
Breast Cancer Res Treat
. 2018 Feb;
169(2):359-369.
PMID: 29388015
Purpose: Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The DCIS score (DS) was validated as a predictor of LR in E5194...
3.
Hartmaier R, Trabucco S, Priedigkeit N, Chung J, Parachoniak C, Vanden Borre P, et al.
Ann Oncol
. 2018 Jan;
29(4):872-880.
PMID: 29360925
Background: Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins...
4.
Cao C, Vasilatos S, Bhargava R, Fine J, Oesterreich S, Davidson N, et al.
Oncogene
. 2016 May;
36(1):133-145.
PMID: 27212032
We have previously demonstrated that crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs) facilitates breast cancer proliferation. However, the underlying mechanisms are largely unknown. Here, we report that...
5.
Reeder A, Attar M, Nazario L, Bathula C, Zhang A, Hochbaum D, et al.
Br J Cancer
. 2015 Apr;
112(9):1461-70.
PMID: 25880007
Background: The mechanisms by which stress hormones impact triple-negative breast cancer (TNBC) etiology and treatment are unclear. We have previously shown that stress hormones, cortisol, and catecholamines induce rapid DNA...
6.
Schneider B, Li L, Shen F, Miller K, Radovich M, ONeill A, et al.
Br J Cancer
. 2014 Aug;
111(6):1241-8.
PMID: 25117820
Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. Methods: A genome-wide association study (GWAS) was performed in the...
7.
Cheng H, Ballman K, Vassilakopoulou M, Dueck A, Reinholz M, Tenner K, et al.
Br J Cancer
. 2014 Aug;
111(6):1065-71.
PMID: 25117817
Background: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate...
8.
van Londen G, Beckjord E, Dew M, Cooper K, Davidson N, Bovbjerg D, et al.
Support Care Cancer
. 2013 Nov;
22(4):937-45.
PMID: 24271937
Background: Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or...
9.
Goss P, Ingle J, Martino S, Robert N, Muss H, Livingston R, et al.
Ann Oncol
. 2012 Oct;
24(2):355-361.
PMID: 23028039
Background: MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen. Patients And Methods: Exploratory subgroup analyses of disease-free survival (DFS), distant...
10.
Ingle J, Tu D, Pater J, Muss H, Martino S, Robert N, et al.
Ann Oncol
. 2008 Mar;
19(5):877-82.
PMID: 18332043
Background: MA.17 evaluated letrozole or placebo after 5 years of tamoxifen and showed significant improvement in disease-free survival (DFS) for letrozole [hazard ratio (HR) 0.57, P = 0.00008]. The trial...